• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

F. Stephen Hodi, MD

Publications

  • Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA.Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.Cancer Immunol Res. 2014 Jul(7):643-54.
    24903021
  • Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D.Bevacizumab plus ipilimumab in patients with metastatic melanoma.Cancer Immunol Res. 2014 Jul(7):632-42.
    24838938
  • Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ.Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.Cancer. 2014 Jun 1(11):1695-701.
    24577748
  • Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M.Melanoma, version 4.2014.J Natl Compr Canc Netw. 2014 May;12(5):621-9.
    24812131
  • Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, Wong P, Wu X, Naidoo J, Page DB, Wolchok JD, Hodi FS.Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.Cancer Immunol Res. 2014 Feb;2(2):127-32.
    24778276
  • Min L, Hodi FS.Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis.Cancer Immunol Res. 2014 Jan;2(1):15-8.
    24778161
  • Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol. 2014 Apr 1;32(10):1020-30.
    24590637
  • Luke JJ, Lezcano C, Hodi FS, Murphy GF.Antitumor Granuloma Formation by CD4+ T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Treatment With Ipilimumab.J Clin Oncol. 2014 Mar 10.
    24616309
  • Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, Liao X, Hodi FS, O'Connell K, Haining WN, Goldstein NR, Canning CM, Soiffer RJ, Ritz J, Hacohen N, Alyea EP, Kim HT, Wu CJ.Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.Blood. 2014 Feb 27;123(9):1412-21.
    24357730
  • Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL, Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, Flaherty K, Cranmer L, Hodi FS, Day BM, Linke R, Hainsworth J.A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.Cancer J.;20(1):18-24.
    24445759
  • O'Regan K, Breen M, Ramaiya N, Jagannathan J, DiPiro PJ, Hodi FS, Van den Abbeele AD.Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence.Cancer Imaging. 2013;13(4):626-32.
    24434078
  • Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, Liao X, Hodi FS, O'Connell K, Haining WN, Goldstein NR, Canning CM, Soiffer RJ, Ritz J, Hacohen N, Alyea EP, Kim HT, Wu CJ.Reversal of in situ T cell exhaustion during effective human anti-leukemia responses to donor lymphocyte infusion.Blood..
  • Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.Cancer. 2013 Oct 15;119(20):3687-95.
    23913718
  • Ott PA, Hodi FS, Robert C.CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.Clin Cancer Res. 2013 Oct 1;19(19):5300-9.
    24089443
  • Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB.The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.Nat Rev Clin Oncol. 2013 Oct;10(10):588-98.
    23982524
  • Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.J Clin Oncol. 2013 Sep 10;31(26):3182-90.
    23775962
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY, .Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.Lancet Oncol. 2013 Sep;14(10):e396-406. Review.
    23993384
  • Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY, .Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.Lancet Oncol. 2013 Sep;14(10):e407-16. Review.
    23993385
  • Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS.Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.Clin Cancer Res. 2013 Jul 15;19(14):3936-43.
    23743568
  • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A.Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.N Engl J Med. 2013 Jul 11;369(2):134-44.
    23724846
  • Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.Ipilimumab for patients with advanced mucosal melanoma.Oncologist. 2013 Jun;18(6):726-32.
    23716015
  • Luke JJ, Hodi FS.Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Oncologist. 2013 Jun;18(6):717-25.
    23709751
  • Fecher LA, Agarwala SS, Hodi FS, Weber JS.Ipilimumab and its toxicities: a multidisciplinary approach.Oncologist. 2013 Jun;18(6):733-43.
    23774827
  • Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS, .Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma.Cancer. 2013 May 1;119(9):1675-82.
    23400564
  • Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, .Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.Clin Cancer Res. 2013 Apr 15;19(8):2232-9.
    23444228
  • Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M.Melanoma, Version 2.2013: Featured Updates to the NCCN Guidelines.J Natl Compr Canc Netw. 2013 Apr 1;11(4):395-407.
    23584343
  • Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J.Hepatotoxicity with combination of vemurafenib and ipilimumab.N Engl J Med. 2013 Apr 4;368(14):1365-6.
    23550685
  • Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Clin Cancer Res. 2013 Mar 1;19(5):1225-31.
    23307859
  • Wu X, Marmarelis ME, Hodi FS.Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.PLoS ONE. 2013;8(2):e56134.
    23418523
  • Jiang X, Zhou J, Giobbie-Hurder A, Wargo JA, Hodi FS.The Paradoxical Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression that is Reversible by MEK and PI3K inhibition.Clin Cancer Res. 2012 Oct 24.
    23095323
  • Chen DS, Irving BA, Hodi FS.Molecular Pathways: Next Generation Immunotherapy: Inhibiting Programmed Death-Ligand 1 and Programmed Death-1.Clin Cancer Res. 2012 Oct 19.
    23087408
  • Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH.When progressive disease does not mean treatment failure: reconsidering the criteria for progression.Journal of the National Cancer Institute. 2012 Oct 17;104(20):1534-41.
    22927506
  • Wu X, Li J, Zhu M, Fletcher JA, Hodi FS.Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.Mol Cancer Ther. 2012 Sep;11(9):1905-14.
    22653968
  • Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM.Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".J Transl Med. 2012;10:83.
    22551296
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med. 2012 Jun 28;366(26):2443-54.
    22658127
  • Salama AK, Hodi FS.Cytotoxic T-Lymphocyte-Associated Antigen-4.Clin Cancer Res. 2011 Apr 5.
    21467163
  • Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS, Dranoff G.Active immunotherapy induces antibody responses that target tumor angiogenesis.Cancer Res. 2010 Dec 15;70(24):10150-60.
    21159637
  • Friedlander P, Hodi FS.Advances in targeted therapy for melanoma.Clin Adv Hematol Oncol. 2010 Sep;8(9):619-35.
    21157411
  • Ma J, Lin JY, Alloo A, Wilson BJ, Schatton T, Zhan Q, Murphy GF, Waaga-Gasser AM, Gasser M, Hodi FS, Frank NY, Frank MH.Isolation of tumorigenic circulating melanoma cells.Biochem Biophys Res Commun. 2010 Nov 26;402(4):711-7.
    20977885
  • Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J.Improved endpoints for cancer immunotherapy trials.Journal of the National Cancer Institute. 2010 Sep 22;102(18):1388-97. Review.
    20826737
  • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010 Aug 19;363(8):711-23.
    20525992
  • Hodi FS.Overcoming immunological tolerance to melanoma: Targeting CTLA-4.Asia Pac J Clin Oncol. 2010 Mar;6 Suppl 1:S16-23. Review.
    20482528
  • Hodi FS, Dranoff G.The biologic importance of tumor-infiltrating lymphocytes.J Cutan Pathol. 2010 Apr;37 Suppl 1:48-53.
    20482675
  • Flaherty KT, Hodi FS, Bastian BC.Mutation-driven drug development in melanoma.Curr Opin Oncol. 2010 May;22(3):178-83. Review.
    20401974
  • Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi TM, Sosman J.Melanoma from bench to bedside: meeting report from the 6th international melanoma congress.Pigment Cell Melanoma Res. 2010 Feb;23(1):14-26.
    20025711
  • Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH.Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells.Cancer Res. 2010 Jan 15;70(2):697-708.
    20068175
  • Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS.Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.Clin Cancer Res. 2009 Dec 1;15(23):7412-20.
    19934295
  • Coit DG,Andtbacka R,Bichakjian CK,Dilawari RA,Dimaio D,Guild V,Halpern AC,Hodi FS,Kashani-Sabet M,Lange JR,Lind A,Martin L,Martini MC,Pruitt SK,Ross MI,Sener SF,Swetter SM,Tanabe KK,Thompson JA,Trisal V,Urist MM,Weber J,Wong MK.Melanoma.J Natl Compr Canc Netw. 2009 Mar;7(3):250-75.
    19401060
  • Jiang X,Zhou J,Yuen NK,Corless CL,Heinrich MC,Fletcher JA,Demetri GD,Widlund HR,Fisher DE,Hodi FS.Imatinib targeting of KIT-mutant oncoprotein in melanoma.Clin Cancer Res. 2008 Dec 1;14(23):7726-32.
    19047099
  • Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL.KIT gene mutations and copy number in melanoma subtypes.Clin Cancer Res. 2008 Nov 1;14(21):6821-8.
    18980976
  • Hodi FS,Fisher DE.Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma.Nat Clin Pract Oncol. 2008 Dec;5(12):696-7.
    18852719
  • Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Day AL, Kruse A, Mac Rae S, Hoos A, Mihm M.CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.Nat Clin Pract Oncol. 2008 Sep;5(9):557-61.
    18665147
  • Sittler T,Zhou J,Park J,Yuen NK,Sarantopoulos S,Mollick J,Salgia R,Giobbie-Hurder A,Dranoff G,Hodi FS.Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.Clin Cancer Res. 2008 Jun 15;14(12):3896-905.
    18559611
  • Oble DA,Mino-Kenudson M,Goldsmith J,Hodi FS,Seliem RM,Dranoff G,Mihm M,Hasserjian R,Lauwers GY.Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis.Am J Surg Pathol. 2008 Aug;32(8):1130-7.
    18545145
  • McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.J Clin Oncol. 2008 May 1;26(13):2178-85.
    18445842
  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE.Major response to imatinib mesylate in KIT-mutated melanoma.J Clin Oncol. 2008 Apr 20;26(12):2046-51.
    18421059
  • Jinushi M, Hodi FS, Dranoff G.Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.Immunol Rev. 2008 Apr;222:287-98. Review.
    18364009
  • Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, LaBaer J.Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.J Proteome Res. 2008 Apr;7(4):1490-9.
    18311903
  • Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G.Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10.
    18287062
  • Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA.Modeling genomic diversity and tumor dependency in malignant melanoma.Cancer Res. 2008 Feb 1;68(3):664-73.
    18245465
  • Hodi FS.Cytotoxic T-lymphocyte-associated antigen-4.Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5238-42. Review.
    17875750
  • Butler MO, Lee JS, Ansn S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell.Clin Cancer Res. 2007 Mar 15;13(6):1857-1867.
    17363542
  • Jinushi M, Hodi FS, Dranoff G.Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9190-5.
    16754847
  • Hodi FS, Dranoff G.Combinatorial cancer immunotherapy.Adv Immunol. 2006;90:341-68. Review.
    16730268
  • Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG.Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.Clin Cancer Res. 2005 Nov 1;11(21):7692-9.
    16278389
  • Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG.Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.Melanoma Res. 2005 Feb;15(1):77-82.
    15714125
  • Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G.Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.J Clin Oncol. 2003 Sep 1;21(17):3343-50.
    12947071
  • Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G.MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients.Cancer Immun. 2003 Mar 17;3:3.
    12747745
  • Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G.Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7.
    12682289
  • Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G.Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3398-403.
    12626761
  • Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G.Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.J Clin Oncol. 2003 Feb 15;21(4):624-30.
    12586798
  • Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG.Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX.Blood. 2002 Sep 15;100(6):2123-31.
    12200376
  • Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG.Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.Arch Dermatol. 2002 Jun;138(6):799-802.
    12056962
  • Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG.Phase II study of paclitaxel and carboplatin for malignant melanoma.Am J Clin Oncol. 2002 Jun;25(3):283-6.
    12040289
  • Hodi FS, Schmollinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, Alyea EP, Yang J, Neuberg D, Mihm M, Dranoff G.ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.Proc Natl Acad Sci U S A. 2002 May 14;99(10):6919-24.
    11983866
  • Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG.Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.Cancer J. 2000 May-Jun;6(3):139-45.
    10882328
  • Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Dranoff G.Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13141-6.
    9789055
  • Hodi FS, Dranoff G.Genetically modified tumor cell vaccines.Surg Oncol Clin N Am. 1998 Jul;7(3):471-85.
    9624213
  • Haluska FG, Hodi FS.Molecular genetics of familial cutaneous melanoma.J Clin Oncol. 1998 Feb;16(2):670-82.
    9469357